StreetAlpha.app
Home › Stocks › VNDA

Vanda Pharmaceuticals Inc. (VNDA)

Healthcare
$3.81
▲ +0.00%
LAST CLOSE · NOV 17

Vanda Pharmaceuticals develops and sells prescription medicines for psychiatric, sleep and neurological conditions. It last closed at $3.81 on Nov 17, up 0.00% on the day. VNDA reports earnings on Wed, Feb 10, 2027.

AI Auto Pilots
Is VNDA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$229.3M
+8.1% vs a year ago
Net income
−$274.8M
−119.9% margin
EPS (diluted)
−$4.62
Free cash flow
−$140.0M
−61.0% margin
Valuation
Market cap
$230.4M
60.5M shares
P/E
–
No P/E while losing money
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$61.9M
At Sep 30
Shareholder equity
$199.9M
Shares outstanding
60.5M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $268.7M$268.7MFY2021FY2022: $254.4M$254.4MFY2022FY2023: $192.6M$192.6MFY2023FY2024: $198.8M$198.8MFY2024FY2025: $216.1M$216.1MFY2025

From VNDA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
-$0.32
$70.1M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated VNDA in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 162.5% upside

Based on 1 analyst who set a price target on VNDA in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $3.81.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $3.81
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
OppenheimerInitiated
Sep 23Buy$10
B. Riley SecuritiesReiterated
Aug 10Buy$12
HC Wainwright & Co.Maintained
Aug 10Buy$20
DateFirmActionRatingPrice target
Sep 23OppenheimerInitiatedBuy$10
Aug 10B. Riley SecuritiesReiteratedBuy$12
Aug 10HC Wainwright & Co.MaintainedBuy$20
Loading…

Whale Options Flow

90D

No whale options trades in VNDA in the last 90 days.

Loading…

See today’s whale options flow across the market →

VNDA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼61 buying vs 100 selling
  • ▲Held by funds +0.9 pts
  • ▼Funds holding -20
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding152172−11.6%
In funds' top 1001−100.0%
Held by funds83.0%82.2%+0.9 pts
New / increased13 / 4827 / 68−35.8%
Reduced / sold out69 / 3155 / 25+25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VNDA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VNDA is in one of them and how their past VNDA trades turned out.

VNDA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VNDA in an article yet. Here's the latest on the wider market.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, D.C. It develops and sells prescription medicines for patients with psychiatric, sleep and neurological conditions. Its marketed products include Fanapt for schizophrenia and bipolar I disorder, HETLIOZ for certain sleep-wake disorders, PONVORY for multiple sclerosis, and NEREUS for preventing vomiting caused by motion. The company also has other medicines in development.

Headquarters
Washington, DC